For three decades, CAR-T therapies failed to work against gastric cancer and other solid tumors. This wasn't for lack of effort: since the first clinical successes in lymphomas in the 1990s, dozens of laboratories have attempted to extend the same technology to solid tumors. None achieved regulatory approval. On June 22, 2026, Shanghai-based biotech CARsgen became the first: China's drug authority NMPA approved Satri-cel (Satricabtagene Autoleucel) for market use. It is the world's first CAR-T product approved for any solid tumor.
The biological problem that waited thirty years
CAR-T cell therapies work on a simple principle: T cells are harvested from a patient, genetically reprogrammed in the laboratory to recognize a specific protein on cancer cells, then reinfused. For blood cancers, the target protein is easily accessible: leukemia cells float freely in the bloodstream and the modified cells eliminate them. With solid tumors, the problem is more fundamental. Solid tumors surround themselves with a hostile microenvironment: regulatory T cells and myeloid-derived suppressor cells secrete molecules that paralyze infiltrating immune cells. Meanwhile, the tumor's accelerated metabolism (Warburg effect) produces high levels of lactate, acidifying the surrounding environment and driving T cells into exhaustion. Add poor infiltration: CAR-T cells often fail to reach tumor tissue in sufficient numbers.
CARsgen solved the infiltration problem with an unusual preconditioning protocol. Before the actual cell infusion, patients receive low-dose nab-paclitaxel, a chemotherapy drug that primes tumor cells for attack, combined with the classic lymphodepletion regimen of cyclophosphamide and fludarabine. This combination opens a pathway into tumor tissue for the immune system. According to CARsgen, this is one of Satri-cel's core innovations.
The target: a normally hidden protein
Satri-cel's target protein is called Claudin 18.2 (CLDN18.2), a component of tight junctions in gastric mucosa. In healthy tissue, Claudin 18.2 sits on the inside of gastric epithelial cells, inaccessible to the immune system. In gastric cancer, cells lose their orderly structure, the protein migrates to the cell surface, and becomes targetable by CAR-T cells. CARsgen developed a humanized anti-CLDN18.2 CAR construct with CD28 and CD3ζ signaling domains, selectively targeting Claudin-18.2-positive tumor cells.
The approval applies to patients with Claudin-18.2-positive, HER2-negative advanced adenocarcinoma of the stomach or gastroesophageal junction who have received at least two prior treatment lines without response. These are patients for whom few options remain.
Clinical data: modest, but meaningful
The regulatory basis is the randomized Phase 2 trial CT041-ST-01, published in 2025 in The Lancet. Patients receiving Satri-cel achieved a median progression-free survival of 3.25 months versus 1.77 months in the control group (physician's choice). Median overall survival was 7.92 months in the Satri-cel arm versus 5.49 months in the comparison group.
For heavily pretreated patients in advanced stages, these are clinically meaningful gains: roughly two additional months of survival for a population with a median prognosis of only five months. Oncologists note caveats, however: the trial was conducted exclusively in China with Chinese patients. Whether results will translate to Western populations, where gastric cancer biology and Claudin-18.2 expression patterns may differ, remains uncertain.
The safety profile was acceptable. Cytokine Release Syndrome (CRS), typical for CAR-T therapies, occurred in 95.5 percent of patients. Only 4.5 percent of CRS cases reached Grade 3 or higher. Notably, ICANS (immune effector cell-associated neurotoxicity syndrome), a dreaded complication in blood cancer CAR-Ts, was not reported in a single patient.
Gastric cancer: a global gap
Gastric cancer is the fifth most common cancer diagnosis globally, with approximately 970,000 new cases annually and around 660,000 deaths. China alone accounts for roughly 47 percent of the global burden. In Germany, the German Cancer Research Center (DKFZ) reports roughly 14,500 new diagnoses yearly, with about 8,500 deaths from the disease. Advanced gastric cancer carries a five-year survival rate below ten percent.
For Satri-cel's target population—patients in the third treatment line and beyond—few approved treatment options currently exist. Existing chemotherapy regimens show very low response rates at this stage. Oncologists at Jiahui International Cancer Center in Shanghai have already enrolled the first international patient, a 59-year-old from New Zealand with advanced gastric cancer, after confirming Claudin-18.2 positivity.
Lin Shen from Peking University Cancer Hospital, involved in the approval trial, described the therapy as a watershed: "Satri-cel fills the gap in late-line treatment of advanced gastric carcinoma and ushers in a new era of cell therapy for solid tumors." CARsgen CEO Zonghai Li emphasized the paradigm shift: the drug marks "the transition from CAR-T therapy in blood cancers to solid tumors."
The access question remains critical. In China, Satri-cel treatment costs are reported at 120,000 to 170,000 US dollars, roughly 60 percent below comparable CAR-T therapies in the United States. For now, the approval primarily benefits private patients and medical tourists. For patients in low-income countries, access remains effectively closed.
FDA has granted RMAT status; EMA grants PRIME status
Satri-cel already holds RMAT (Regenerative Medicine Advanced Therapy Designation) and Orphan Drug status in the United States. In the EU, the product has EMA PRIME designation plus Orphan Designation. Both accelerate the approval pathway but guarantee no timeline. CARsgen is conducting the ongoing Phase Ib/II trial ELIMYN18.2 (CT041-ST-02) in North America in patients with Claudin-18.2-positive gastric and pancreatic cancer. The company has not yet communicated specific submission timelines for FDA or EMA.
In parallel, CARsgen is expanding the indication: a Phase I trial examines Satri-cel as adjuvant therapy after resection in pancreatic cancer; another approach targets first-line use in gastric carcinoma. Claudin 18.2 is overexpressed in other tumor types as well, including cholangiocarcinoma and esophageal cancer.
The approval is a proof of principle, not an immediate solution for Western patients. Today, a patient in Germany with advanced gastric cancer meeting biomarker criteria would need to travel to Shanghai and self-fund. North American clinical data supporting an FDA or EMA submission are expected earliest in 2027.